clinical trial · NCT04406896
The Effect of Reduced Liver Function on Selatogrel Pharmacokinetics
Viatris Innovation GmbH·phase1·completed·n = 24
Healthy SubjectsHepatic ImpairmentSelatogrel
brief summary
This is a prospective, single-center, open-label, single-dose, Phase 1 study, to assess the effect of mild and moderate hepatic impairment due to liver cirrhosis on the pharmacokinetics of selatogrel (ACT-246475).
started
Jul 22, 2020
primary completion
Oct 23, 2020
completion
Oct 23, 2020
last updated
Jul 4, 2025
official title
An Open-label, Single-dose, Phase 1 Study to Evaluate the Pharmacokinetics of Selatogrel in Subjects With Mild and Moderate Hepatic Impairment Compared to Matched Healthy Subjects
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol